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Abstract
A genome-wide association scan of type 1 diabetic patients from the GoKinD collections previously identified four novel
diabetic nephropathy susceptibility loci that have subsequently been shown to be associated with diabetic nephropathy in
unrelated patients with type 2 diabetes. To expand these findings, we examined whether single nucleotide polymorphisms
(SNPs) at these susceptibility loci were associated with diabetic nephropathy in patients from the Joslin Study of Genetics of
Nephropathy in Type 2 Diabetes Family Collection. Six SNPs across the four loci identified in the GoKinD collections and 7
haplotype tagging SNPs, were genotyped in 66 extended families of European ancestry. Pedigrees from this collection
contained an average of 18.5 members, including 2 to 14 members with type 2 diabetes. Among diabetic family members,
the 9q21.32 locus approached statistical significance with advanced diabetic nephropathy (P=0.037 [adjusted P=0.222]).
When we expanded our definition of diabetic nephropathy to include individuals with high microalbuminuria, the strength
of this association improved significantly (P=1.42610
23 [adjusted P=0.009]). This same locus also trended toward
statistical significance with variation in urinary albumin excretion in family members with type 2 diabetes (P=0.032
[adjusted P=0.192]) and in analyses expanded to include all relatives (P=0.019 [adjusted P=0.114]). These data increase
support that SNPs identified in the GoKinD collections on chromosome 9q21.32 are true diabetic nephropathy susceptibility
loci.
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Introduction
Increased urinary albumin excretion, in both the microalbumi-
nuric and proteinuric ranges, is a hallmark of diabetic nephrop-
athy (DN) [1,2]. Clinically, DN is a progressive disease that
advances through characteristic stages. For many diabetic patients,
elevated urinary albumin excretion is coupled with declining renal
function. In a large proportion of these individuals, renal function
continues to deteriorate until end-stage renal disease (ESRD) is
reached.
Despite a large body of evidence that favors a genetic basis for
susceptibility to DN, identification of the genetic factors that
contribute to its risk has proven challenging [3–12]. While no
single, major DN susceptibility gene has yet been identified,
growing support for several loci identified though genome-wide
surveys of common genetic variants has recently begun to emerge
[13–22]. Included among the studies contributing to this success is
our recent genome-wide association (GWA) scan of unrelated type
1 diabetic (T1D) subjects from the Genetics of Kidneys in Diabetes
(GoKinD) study collections [18]. In this report, we identified
strong associations at several common single nucleotide polymor-
phisms (SNPs, minor allele frequencies .5%) located across four
distinct chromosomal regions. Three of these loci, located on
chromosome 9q21.32 near the FRMD3 gene, chromosome
11p15.4 at the CARS gene, and chromosome 13q33.3 at the
MYO16/IRS2 locus, have since been confirmed in multiple diverse
collections of unrelated T1D or type 2 diabetic (T2D) patients
[18,20,22]. A more recent meta-analysis of T1D nephropathy,
defined as end-stage renal disease (ESRD), in European-derived
populations, however, failed to confirm these, as well as several
other, previously reported genetic associations; reinforcing the
need for further investigation of these and other loci to truly
understand their role in the genetic basis of DN [23].
To address this need, we chose to extend our focused evaluation
of the loci identified in GoKinD to a family-based association
study of patients from the Joslin Study of Genetics of Nephropathy
in Type 2 Diabetes Family Collection. In addition to dichotomized
comparisons of DN status, we investigated whether any of these
loci were associated with quantitative variation in urinary albumin
in this collection.
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Study Patients and Ethics Statement
The present study investigated 1,221 individuals (798 with
direct genotype and phenotype information) from 66 extended
families of European ancestry from the Joslin Study of Genetics of
Nephropathy in Type 2 Diabetes Family Collection. The protocols
and informed consent procedures used in this study were approved
by the Committee on Human Subjects of the Joslin Diabetes
Center.
The recruitment of the Joslin Study of Genetics of Nephropathy
in Type 2 Diabetes Family Collection has previously been
described [9,11,12,24]. Briefly, between 1993 and 2003, families
with an apparent autosomal dominant mode of inheritance of
T2D, irrespective of their nephropathy status, were recruited to
the Joslin Study of Genetics of Nephropathy in Type 2 Diabetes
Family Collection through T2D probands receiving medical care
at the Joslin Clinic. After obtaining informed written consent,
trained recruiters administered previously described study proto-
cols that included a structured interview, seated blood pressure
measurements, and the collections of blood and urine samples.
ESRD status for members of this collection was updated as of
August 2008 through the United States Renal Data System.
Classification of Nephropathy Status
Methods for measuring albumin and creatinine in a random
urine sample for determination of the albumin-to-creatinine ratio
(ACR) and defining normoalbuminuria, microalbuminuria, or
proteinuria were described previously [25]. ACR values were used
to assign albuminuria status to all individuals included in our
analysis; individuals with ACR values less than 30 mg/mg,
between 30 mg/mg and 300 mg/mg, between 100 mg/mg and
300 mg/mg, and above 300 mg/mg were considered normoalbu-
minuric, microalbuminuric, high microalbuminuric, and protein-
uric, respectively. Individuals with ESRD were assigned ACR
values of 3500 mg/mg. For quantitative trait analyses, a log
transformation was applied to the measured/assigned ACR
values.
Genotyping
Six SNPs across the four loci identified in the GoKinD
collections were selected for inclusion in the present study;
including rs39075 on chromosome 7p14.3, rs1888747 and
rs10868025 on chromosome 9q21.32, rs451041 on chromosome
11p15.4, and rs1411766 and rs9521445 on chromosome 13q33.3.
Seven additional haplotype tagging SNPs (two on chromosomes
7p14.3, 11p15.4, and 13q33.3 and one on chromosome 9q21.32)
were selected using Haploview [26] to capture the major
haplotypes (haplotype frequencies $0.05) for the linkage disequi-
librium (LD) blocks containing the SNPs identified in GoKinD. All
thirteen SNPs were genotyped using Taqman (Applied Biosystems,
Foster City, CA) technology by the Genetics Core of the Diabetes
and Endocrinology Research Center at the Joslin Diabetes Center
in accordance with the manufacturer’s protocols.
Statistical Analysis
Each SNP was tested for deviation from Hardy-Weinberg
equilibrium using a chi-square goodness-of-fit test. Family-based
single-marker association tests were performed using the FBAT
software under an additive model using a conservative empirical
variance estimator to test the null hypothesis of no linkage and no
association [27]. For all dichotomous trait analyses, allele
transmissions from parent to affected and unaffected family
members were contrasted by weighting their contribution to the
FBAT test statistic using the estimated population prevalence of
DN among diabetic individuals (i.e., 30%; ‘Affected and Unaf-
fected’ analyses). Family-based association testing of allele
transmission from parents to only affected offsprings was also
performed (i.e., ‘Affecteds Only’ analyses). The HBAT procedure
in FBAT was used to estimate haplotype frequencies and perform
haplotype-specific and global tests of association. P-values
,8.33610
23 (0.05/6) were considered statistically significant.
Results
A total of 1,221 individuals from 66 extended families of
European ancestry from the Joslin Study of Genetics of
Nephropathy in Type 2 Diabetes Family Collection, including
798 (382 non-diabetic and 416 diabetic) members with direct
genotype and phenotype information, were included in the present
study. Pedigrees from these families included an average of 18.5
members, ranging in size from 6 to 39 members, and formed a
total of 318 nuclear families. Four to 26 individuals from each
family, including 2 to 14 members with diabetes, had DNA
available for genotyping. The mean age of diabetes diagnosis
within these families, was 43.4616.8 years.
Ninety-seven (23.3%) diabetic individuals were considered to
have advanced DN (proteinuria, n=40, or ESRD, n=57) while
312 (75.0%) were classified as non-DN controls. To improve
power to detect significant associations between DN and SNPs
identified in the GoKinD collections, we also expanded our
nephropathy phenotype to include individuals with less severe
nephropathy. For these comparisons, dichotomized cases included
28 additional individuals with high microalbuminuria. Seven
diabetic individuals did not have ACR data available for
classification of their nephropathy status or for the quantitative
analysis of this trait; these individuals were excluded from all
analyses. Proteinuria developed in 3 (0.8%) non-diabetic individ-
uals. Clinical characteristics for examined members of the Joslin
Study of Genetics of Nephropathy in Type 2 Diabetes Family
Collection included in this study are provided in Table 1.
The distribution of relative pairs in the Joslin Study of Genetics
of Nephropathy in Type 2 Diabetes Family Collection based on
their relationship and DN status are provided in Table 2. These 66
extended families generated a total of 6,421 relative pairs; 1,026 of
whom are concordant for diabetes. The diabetic relative pairs
include 53 relative pairs that are concordant for advanced DN,
239 relative pairs that are disconcordant for advanced DN, 88
relative pairs concordant for DN, and 329 relative pairs
disconcordant for DN. Additionally, there are 15 relative pairs
concordant for ESRD and 134 relative pairs disconcordant for this
phenotype.
No deviation from Hardy-Weinberg equilibrium was observed
among the 13 SNPs included in this study in the entire collection
or in analyses performed separately in affected and unaffected
individuals (P.0.05).
Family-based association analyses of 6 SNPs across the four loci
identified in the GoKinD GWA scan were performed in diabetic
relatives as well as in all relatives combined. Among diabetic
family members, rs1888747 on chromosome 9q21.32 showed
evidence of association with advanced nephropathy among
diabetic family members (affecteds only: P=0.029 [adjusted
P=0.174], Z=2.18; affecteds and unaffecteds: P=0.037 [adjusted
P=0.222], Z=2.08, Table 3). When we expanded our definition
of DN to include individuals with high microalbuminuria, the
strength of this association improved significantly (affecteds only:
P=1.74610
23 [adjusted P=0.010], Z=3.13; affecteds and
unaffecteds: P=1.42610
23 [adjusted P=0.009], Z=3.19,
Family-Based Analysis in Diabetic Nephropathy
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the same direction as initially reported in the GoKinD collections.
Although no other SNPs achieved statistical significance, variants
on 7p14.3 and 13q33.3 shared directionality with associations
identified in GoKinD (Table 3 and Table 4). Among all family
members, only rs1888747 was nominally associated with nephrop-
athy in analyses that included high microalbuminurics (affecteds
only: P=0.026 [adjusted P=0.156], Z=2.23; affecteds and
unaffecteds: P=0.017 [adjusted P=0.102], Z=2.38, Table S1
and Table S2). Lastly, dichotomous analyses restricted to diabetic
family members with ESRD showed modest evidence of a
statistical association with rs1888747 (affecteds only: P=0.036,
Table 1. Clinical characteristics of 798 examined members from 66 families from the Joslin Study of Genetics of Nephropathy in
Type 2 Diabetes Family Collection.
Clinical characteristic Non-diabetic individuals Diabetic individuals
n 382 416
Men (%) 43.7 45.2
Age (years) 46.7617.2 57.5615.7
Age of diabetes diagnosis (years) --- 43.4616.8
Duration of diabetes (years) --- 14.1611.8
Diabetes treatment (%)
Insulin only --- 40.6
Insulin and oral agents --- 6.0
Oral agents only --- 35.8
Diet --- 17.6
Treatment with ACE inhibitors (%) 3.7 18.8
BMI (kg/m
2) 27.565.6 30.166.7
HbA1c (%) 5.560.5 7.661.5
Systolic blood pressure (mmHg) 121.5618.0 137.3620.4
Diastolic blood pressure (mmHg) 77.2610.1 78.2610.3
Treatment with antihypertensive medication (%) 14.0 45.0
Treatment with ACE inhibitors (%) 3.7 18.8
ACR ( mg/mg), median (25
th and 75
th percentiles) 6.0 (4.0, 9.0) 17.0 (7.0, 237.2)
*
Patients with microalbuminuria (%) 22 (5.8) 72 (17.3)
Patients with high microalbuminuria
{ (%) 7 (1.8) 28 (6.7)
Patients with proteinuria (%) 3 (0.8) 40 (9.6)
Patients with ESRD (%) --- 57
{ (13.7)
Baseline clinical characteristics are presented as mean values 6 standard deviation.
HbA1c, glycosylated hemoglobin. ESRD, end-stage renal disease.
*ESRD patients were assigned ACR values of 3500 mg/mg.
{High microalbuminuria was defined as an ACR between 100 and 300 mg/mg.
{ESRD status was updated for members of this collection through the United States Renal Data System as of August 2008.
doi:10.1371/journal.pone.0060301.t001
Table 2. Summary of the relative pairs in the 66 families from the Joslin Study of Genetics of Nephropathy in Type 2 Diabetes
Family Collection according to diabetes and nephropathy status.
Advanced DN DN ESRD
Relationship All pairs
All diabetic
pairs
Concordant
pairs
Discordant
pairs
Concordant
pairs
Discordant
pairs
Concordant
pairs
Discordant
pairs
Sib-pairs 1127 416 21 106 33 139 6 57
Half-sibs 51 14 1 1 1 1 0 1
Cousins 862 164 12 42 18 57 2 19
Parent-child 1674 135 8 29 11 44 4 19
Grandparent-Grandchild 1148 20 0 6 0 6 0 4
Avuncular 1559 277 11 55 25 82 3 34
All pairs 6421 1026 53 239 88 329 15 134
Advanced DN = diabetic individuals with proteinuria or ESRD; DN = diabetic individuals with high microalbuminuria, proteinuria, or ESRD.
doi:10.1371/journal.pone.0060301.t002
Family-Based Analysis in Diabetic Nephropathy
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this SNP, however, did not achieve statistical significance when a
conservative Bonferroni correction was applied (adjusted P.0.05).
In quantitative trait analyses, rs1888747 on chromosome
9q21.32 was similarly shown to be associated with logACR
among diabetic family members (P=0.030 [adjusted P=0.180],
Z=2.17, Table 6) and in analyses extended to all family members
in the Joslin Study of Genetics of Nephropathy in Type 2 Diabetes
Family Collection (P=0.017 [adjusted P=0.102], Z=2.39, Table
S3). Controlling for reported ACE inhibitor treatment weakened
the association between rs1888747 and albuminuria among
diabetic family members and all family members (P=0.217
[adjusted P=1.00], Z=1.24 and P=0.121 [adjusted P=0.726],
Z=1.55, respectively) while associations at rs10868025 (also
located on chromosome 9q21.32) improved (diabetic family
members: P=0.012 [adjusted P=0.072], Z=2.50; all family
members: P=0.033 [adjusted P=0.198], Z=2.13).
No additional associations were observed between the remain-
ing GoKinD SNPs and logACR in analyses either restricted to
diabetic individuals or in those extended to include all available
family members.
To further examine the susceptibility loci identified in GoKinD,
we genotyped haplotype tagging SNPs across each locus and
performed family-based multi-marker analyses for each nephrop-
athy phenotype using the HBAT procedure in FBAT. Haplotypes
formed by genotyped SNPs on chromosomes 7p14.3, 11p15.4,
and 13q33.3 were not associated with any of the examined
nephropathy phenotypes in analyses of diabetic individuals or in
those performed in all family members (global P.0.05, data not
shown). In contrast, haplotypes on chromosome 9q21.32 showed
evidence of association with advanced nephropathy, nephropathy
and logACR among diabetic family members (Table 7 and
Table 8). While no haplotype on 9q21.32 was more strongly
associated with nephropathy or logACR than the individual SNPs
at this locus, the GTA haplotype, which is comprised of the risk
alleles for both rs1888747 and rs10868025, is more strongly
associated with an increased risk of advanced nephropathy than
any individual SNP at this locus (affecteds only: P=0.012,
Z=2.50; affecteds and unaffecteds: P=0.018, Z=2.37, Table 7).
None of the genotyped haplotype tagging SNPs were associated
with nephropathy in single marker analyses (Tables S4 through
S9).
Discussion
Our GWA scan of the GoKinD collections identified strong
association at four distinct chromosomal regions, including loci on
chromosomes 9q21.32, 11p15.4, and 13q33.3 that have since been
confirmed in multiple collections comprised of unrelated T1D or
T2D subjects [18,20–22]. In the present report, we extend these
findings further by providing additional support for associations at
chromosome 9q21.32 in a large collection of related T2D patients
from the Joslin Study of Genetics of Nephropathy in Type 2
Diabetes Family Collection. In this study, a statistically significant
association was observed between this locus and the risk of high
microalbuminuria, proteinuria, and ESRD among diabetic
individuals in these families.
DN is well-recognized to be a complex disease, characterized by
both abnormalities in urinary albumin excretion and declining
renal function. While most patients with DN exhibit some degree
of elevated urinary albumin excretion, for some, this abnormality
is concurrent with impaired renal function; a subset of these
individuals eventually require renal replacement therapy. This
phenotypic heterogeneity suggests that multiple factors, some
genetic and some non-genetic, contribute to the distinct stages of
DN. In the present study, we report evidence of association at the
9q21.32 locus with advanced DN (i.e., proteinuria and ESRD).
The strength of these associations improved significantly when we
expanded our nephropathy phenotype to include individuals with
less severe DN (i.e., patients with high microalbuminuria, ACR
values .100 mg/mg). Based on these findings, we hypothesize that
variation at this locus contributes to the early stages of
nephropathy in diabetes. Furthermore, we hypothesize that other
genetic factors are likely involved in the progression of DN and the
decline in renal function that accompanies the latter stages of this
disease process.
Table 6. Family-based association analysis between DN-associated SNPs and logACR among diabetic family members.
SNP (risk allele)
* Chr. Allele
Allele
Frequency # Families S-E(S) Var(S) Z score
P-value (adjusted P-
value)
rs39075 (G) 7p14.3 G 0.554 58 36.71 872.53 1.24 0.214
A 0.446 58 236.71 872.53 21.24 (1.00)
rs1888747 (G) 9q21.32 G 0.690 54 54.68 636.86 2.17 0.030
C 0.310 54 254.68 636.86 22.17 (0.180)
rs10868025 (A) 9q21.32 A 0.601 53 38.16 528.18 1.66 0.097
G 0.399 53 238.16 528.18 21.66 (0.582)
rs451041 (A) 11p15.4 A 0.561 55 11.42 640.33 0.45 0.652
G 0.439 55 211.42 640.33 20.45 (1.00)
rs1411766 (A) 13q33.3 G 0.598 55 232.54 834.93 21.13 0.260
A 0.402 55 32.54 834.93 1.13 (1.00)
rs9521445 (A) 13q33.3 A 0.548 51 16.93 716.00 0.63 0.527
C 0.452 51 216.93 716.00 20.63 (1.00)
# Families = number of nuclear families informative for the FBAT analysis.
S-E(S) = observed minus the expected transmission for each allele.
Var(S) = variance of the observed transmission for each allele.
Z score: positive values indicate risk alleles, negative values indicate protective alleles.
*Risk allele reported in Pezzolesi et al.[ 1 8 ]
doi:10.1371/journal.pone.0060301.t006
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now been confirmed in four distinct collections; T1D patients from
the GoKinD collections, the Joslin Study of Genetics of
Nephropathy in Type 2 Diabetes Family Collection, Caucasian
participants from the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications
(DCCT/EDIC) study [18], and African Americans with ESRD
due to T2D [21]. In addition to these studies, a strong protective
affect of the rs1888747 DN-risk allele observed in populations of
European ancestry has recently been reported in unrelated
Japanese T2D patients with microalbuminuria [20]; a notable
finding that may be attributed to allelic heterogeneity resulting
from the ancestral backgrounds of these two ethnic groups.
Despite being quite underpowered, in this study Maeda et al.
identified a strong association at rs1888747 in a comparison of
only 32 microalbuminuric patients who progressed to overt
proteinuria and 168 individuals who remained microalbuminuric
(i.e., non-progressors).
Additional support for a role of this locus in nephropathy comes
from a genetic study of albuminuria quantitative trait loci (QTL)
performed in an intercross of albuminuria resistant and susceptible
mouse strains [28]. Using this approach, Sheehan et al. were able
to localize a QTL associated with increased urinary albumin on
mouse chromosome 4, a region homologous to the DN-associated
locus on chromosome 9q21.32 seen in human populations. This
striking concordance between human and mouse suggests that a
common disease mechanism may link these renal damage
phenotypes.
A major challenge in dissecting the genetic basis of complex
traits, including DN, is that many of the common variants that
have been reproducibly shown to be associated with disease
explain only a modest proportion of the overall risk of disease.
Although less powerful than population-based designs, family-
based approaches such as the one employed in our study will prove
crucial in uncovering variants that have much larger contributions
to the genetic basis of disease as rare variants that are expected to
explain a larger proportion of the heritability of a given phenotype
are enrich in related individuals.
The present study has modest power (,80%) to detect similar
effects as those observed by Pezzolesi et al. [18]. Despite this
limitation, our analysis increases support that previously reported
associations at the 9q21.32 locus are genuine diabetic nephropathy
susceptibility loci and, given the limited power of our study,
suggest that the true effect sizes attributed to variants at this locus
may in fact be larger than previously estimated. More specifically,
the associations identified in the GoKinD collections at the
9q21.32 locus and confirmed in the Joslin Study of Genetics of
Nephropathy in Type 2 Diabetes Family Collection occur at
common SNPs (risk allele frequency < 60–70%) of modest effect
(odds ratio=1.40–1.50). It remains possible that this association is
due to the presence of a ‘synthetic association’ caused by one or
more rare variants located some distance from the observed
associations [29]. Carriers of the rs1888744 risk allele in our
families are potential future candidates for targeted next-genera-
tion sequencing of this locus to identify rare variants that may
explain a substantial proportion of the heritability of DN risk
observed in these families.
In contrast to studies of unrelated cases and controls, family-
based designs, such as the one used in the present study, are robust
to population admixture and stratification. Additionally, family
members also tend to have more homogeneity of environmental
factors that could confound genetic associations with the
phenotype of interest. Despite these advantages, we acknowledge
that the present study is not without its limitations. Patients in
Joslin Study of Genetics of Nephropathy in Type 2 Diabetes
Family Collection were recruited irrespective of their nephropathy
status and their phenotypic characteristics were primarily derived
from baseline data taken at the time of enrollment. Understanding
the natural history of diabetic nephropathy and recognizing the
limitations of this cross-sectional assessment of kidney phenotypes,
we chose to use the USRDS database to track individuals that
progressed to ESRD. Individuals who might have progressed to
ESRD but refused renal replacement therapy are not represented
in USRDS and, depending on their renal status at baseline, may
have misclassification of their renal phenotype. In lieu of
longitudinal follow-up of all members of the Joslin Study of
Genetics of Nephropathy in Type 2 Diabetes Family Collection,
we recognize that the potential misclassification of these individ-
uals is a limitation of our study. Importantly, however, we note
that any phenotypic misclassification due to our inability to track
participants who refused renal replacement therapy is independent
of their carrier status of DN risk and/or non-risk alleles; the
resulting non-differential misclassification could only have biased
our findings toward the null. A second limitation worthy of
discussion is the potential competing risk of death prior to the
development of ESRD. Because of the high rate of mortality
Table 8. Family-based haplotype analysis between chromosome 9q21.32
* haplotypes and logACR among diabetic family
members.
Haplotype Estimated Frequency # Families S-E(S) Var(S) Z score P-value
GTA 0.437 62 63.05 904.53 2.10 0.036
CTG 0.310 54 246.27 743.97 21.70 0.090
GGA 0.163 42 228.61 825.82 21.00 0.320
GTG 0.088 34 11.89 276.38 0.72 0.474
Global P-value 0.192
*9q21.32 haplotypes: rs1888747, rs1929547, and rs10868025.
Haplotypes with estimated frequencies $0.01 are provided and were used to calculate global P-values.
#Families = number of nuclear families informative for the HBAT analysis; a minimum of 5 informative families for each haplotype was required to compute global
tests.
S-E(S) = observed minus the expected transmission for each haplotype.
Var(S) = variance of the observed transmission for each haplotype.
Z score: positive values indicate risk haplotypes, negative values indicate protective haplotypes.
Associations achieving nominal significance (P-value,0.05) are indicated in bold.
doi:10.1371/journal.pone.0060301.t008
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PLOS ONE | www.plosone.org 9 March 2013 | Volume 8 | Issue 3 | e60301experienced by diabetic patients with ESRD, variants associated
with this phenotype may alternatively be associated with survival
in the presence of severe kidney disease. Although the present
study lacks the power to formally assess whether the effects of
variants at the 9q21.32 locus differ according to duration of
ESRD, we have previously shown that the odds ratios for these
variants are consistent across tertiles of ESRD duration in patients
with T1D and ESRD, suggesting that these associations are not
due to survival bias [18].
rs1888747 lies approximately 2 kilo-basepair upstream of FRMD3,a
gene that we have previously shown to be expressed in both human
kidney mesangial cells and proximal tubular cells [18]. Additional work
has further demonstrated that FRMD3 is also expressed in human
podocytes and that its protein product, the 4.1O protein, interacts with
nephrin, podocin, and actin, suggesting this protein is involved in
maintaining the function and integrity of the slit diaphragm
(unpublished data). Most recently, we have shown that rs1888747’s
risk allele generates a transcription factor binding site in a repressive
promote module that is shared by multiple members of the bone
morphogenetic protein (BMP) signaling pathway; a pathway that has
previously been implicated in the development of DN [30,31].
Hierarchical clustering of expression data for FRMD3 and its co-
expressed transcripts suggests that these genes are linked to early
progression in DN [30]. Coupled with the strong association we
observed at this locus in diabetic family members with less severe DN
in the present study, we hypothesize that the 9q21.32 locus contributes
to glomerular injury early in DN’s pathogenesis.
In summary, our study provides further evidence that the
9q21.32 region is a susceptibility locus for DN. Coupled with its
proximity to the association at this locus, FRMD3 appears to be
both a strong positional and biological candidate gene for DN.
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